Doc code: IDS
Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(**Not for submission under 37 CFR 1.99)**

Application Number	10785230
Filing Date	2004-02-26
First Named Inventor	Tadamitsu Kishimoto
Art Unit	1642
Examiner Name	Laura B. Goddard
Attorney Docket Number	046124-5042-01

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	0666868	EP	B2	1995-08-16	Genentech, Inc.		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B.G

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10785230
	Filing Date	2004-02-26
	First Named Inventor	Tadamitsu Kishimoto
	Art Unit	1642
	Examiner Name	Laura B. Goddard
	Attorney Docket Number	046124-5042-01

	1	Aluti et al. (1997), The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood, J. Exp Med. 185:111-20.	☐
	2	Amara et al. (1997), HIV coreceptor downregulation as antiviral principle: SDF-1 alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication, J. Exp Med. 186:139-46.	☐
	3	Asahara et al. (1997), Isolation of putative progenitor endothelial cells for angiogenesis, Science 275:964-7.	☐
	4	Bouck et al. (1996), How tumors become angiogenic, Adv Cancer Res. 69:135-74.	☐
	5	Carmeliet (1996), Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele, Nature 380:435-9.	☐
	6	Carmeliet P, Jain RK. (2000), Angiogenesis in cancer and other diseases, Nature 407:249-57.	☐
	7	Chen et al. (2003), Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in Vitro, Cancer Res. 63:4801-4	☐
	8	Ferrara et al. (1996), Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene, Nature 380: 439-42.	☐
	9	Folkman, J. (1971), Tumor angiogenesis: Therapeutic Implications. New Engl. J. Med. 285:1182-6.	☐
	10	Folkman, J. (1990), What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst. 82:4-6.	☐
	11	Haeberlin et al. (1993), In vitro evaluation of dexamethasone-beta-D-glucuronide for colon-specific drug delivery, Pharm Res. 10:1553-62.	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B.G

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10785230
	Filing Date	2004-02-26
	First Named Inventor	Tadamitsu Kishimoto
	Art Unit	1642
	Examiner Name	Laura B. Goddard
	Attorney Docket Number	046124-5042-01

	12	Leon, L. (2005), Invited review: The use of gene knockout mice in thermoregulation studies, J. Thermal Biol. 30:273-88.	☐
	13	Ma et al. (1998), Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice, Proc Natl Acad Sci USA 95:9448-53.	☐
	14	Müller, U. (1999), Ten years of gene targeting: targeted mouse mutants, from vector design to phenotype analysis. Mechanism of Development 82:3-21.	☐
	15	Shalaby et al. (1995), Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice, Nature 376: 62-6.	☐
	16	Smith et al. (2004), CXCR4 regulates growth of both primary and metastatic breast cancer, Cancer Res. 64: 8604-12.	☐
	17	Spano et al. (2004), Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome, Ann Oncol. 15:613-7.	☐
	18	Weis et al. (2008), Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK, J. Cell Biol. 181:43-50.	☐
	19	Zou et al. (1998), Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development, Nature 393:524-5.	☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Laura B. Goddard/	Date Considered	04/02/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B.G